About Dermavant
Dermavant is a company based in Phoenix (United States) founded in 2016 was acquired by Organon in September 2024.. Dermavant has raised $160 million across 2 funding rounds from investors including Marathon Asset Management, NovaQuest Capital Management and Organon. Dermavant offers products and services including VTAMA Cream. Dermavant operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Sol-Gel Technologies, Bausch Health and Hugel, among others.
- Headquarter Phoenix, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dermavant Sciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$160 M (USD)
in 2 rounds
-
Latest Funding Round
$160 M (USD), Series D
Jun 08, 2021
-
Investors
Marathon Asset Management
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Organon
(Sep 18, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dermavant
Dermavant offers a comprehensive portfolio of products and services, including VTAMA Cream. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cream for treating chronic skin conditions like psoriasis.
Unlock access to complete
Unlock access to complete
Leadership Team
88 people
Software Development Team
55 people
Finance and Accounting
29 people
Data Analysis and Operations Team
22 people
Legal and Compliance
19 people
Operations Team
17 people
Product Management Team
15 people
Human Resources and Administration
14 people
Unlock access to complete
Funding Insights of Dermavant
Dermavant has successfully raised a total of $160M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $160 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series D — $160.0M
-
First Round
First Round
(08 Jun 2021)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Debt – Conventional - Dermavant | Valuation |
investors |
|
| Jun, 2021 | Amount | Series D - Dermavant | Valuation | Marathon Asset Management , NovaQuest Capital Management |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dermavant
Dermavant has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Marathon Asset Management, NovaQuest Capital Management and Organon. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm focused on life science and healthcare companies
|
Founded Year | Domain | Location | |
|
Diversified investment management services are provided across asset classes.
|
Founded Year | Domain | Location | |
|
Organon is focused on improving women's health globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dermavant
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dermavant
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dermavant Comparisons
Competitors of Dermavant
Dermavant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Sol-Gel Technologies, Bausch Health and Hugel, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dermavant
Frequently Asked Questions about Dermavant
When was Dermavant founded?
Dermavant was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Where is Dermavant located?
Dermavant is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
Who is the current CEO of Dermavant?
Todd Zavodnick is the current CEO of Dermavant.
Is Dermavant a funded company?
Dermavant is a funded company, having raised a total of $160M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $40M, raised on Jun 08, 2021.
What does Dermavant do?
Dermavant was founded in 2016 and is headquartered in Phoenix, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are developed for inflammatory skin conditions. The lead candidate, DMVT-505, targets psoriasis and atopic dermatitis by modulating AhR and inhibiting proinflammatory factors. Additional products include DMVT-502, in Phase 1 trials for atopic dermatitis and vitiligo, and DMVT-504 for primary focal hyperhidrosis.
Who are the top competitors of Dermavant?
Dermavant's top competitors include Revance Therapeutics, Bausch Health and Sol-Gel Technologies.
What products or services does Dermavant offer?
Dermavant offers VTAMA Cream.
Who are Dermavant's investors?
Dermavant has 3 investors. Key investors include Marathon Asset Management, NovaQuest Capital Management, and Organon.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.